HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE

(19)

(11)

EP 1 636 268 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	21.03.2012 Bulletin 2012/12

(45)	Mention of the grant of the patent:
	15.02.2012 Bulletin 2012/07

(21)	Application number: 04776252.1

(22)	Date of filing: 01.06.2004

(51)

International Patent Classification (IPC):

C07K 16/18^(2006.01)

(86)	International application number:
	PCT/US2004/017514

(87)	International publication number:
	WO 2004/108895 (16.12.2004 Gazette 2004/51)

(54)	HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID PEPTIDE HUMANISIERTE ANTIKÖRPER, DIE BETA AMYLOID-PEPTID ERKENNEN ANTICORPS HUMANISES QUI RECONNAISSENT LE PEPTIDE BETA-AMYLOIDE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL HR LT LV MK

(30)

Priority:

30.05.2003 US 474654 P

(43)	Date of publication of application:
	22.03.2006 Bulletin 2006/12

(73)	Proprietors:
	Janssen Alzheimer Immunotherapy Dublin 2 (IE) Wyeth LLC Madison, NJ 07940 (US)

(72)	Inventors:
	BASI, Guriq Palo Alto, CA 94303 (US) SALDANHA, Jose, W. Enfield, EN1 3BD (GB) BARD, Frédérique Pacifica, CA 94044 (US)

(74)	Representative: Mercer, Christopher Paul
	Carpmaels & Ransford One Southampton Row London WC1B 5HA London WC1B 5HA (GB)

(56)

References cited: :

EP-A1- 0 921 189
WO-A2-02/088306
US-B1- 6 743 427

WO-A-95/07301
US-A1- 2004 082 762
US-B1- 6 750 324

BARD F ET AL: "Epitope and isotype specificities of antobodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 4, 18 February 2003 (2003-02-18), pages 2023-2028, XP002982464 ISSN: 0027-8424
QUEEN C ET AL: "A HUMANIZED ANTIBODY THAT BINDS TO THE INTERLEUKIN 2 RECEPTOR" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 86, no. 24, 1 December 1989 (1989-12-01), pages 10029-10033, XP000310534 ISSN: 0027-8424
SALDANHA J W ET AL: "A single backmutation in the human kIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells" MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 36, 1999, pages 709-719, XP007901434 ISSN: 0161-5890
SOLOMON B.: 'Immunological approaches as therapy for Alzheimer's disease' EXPERT OPIN BIOL THER. vol. 2, no. 8, December 2002, pages 907 - 917, XP002971402
HOLTZMAN D.M. ET AL: 'Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease' ADVANCED DRUG DELIVERY REVIEWS vol. 54, no. 12, pages 1603 - 1613, XP002982465
DODEL R.C. ET AL: 'Immunotherapy for Alzheimer's disease' LANCET NEUROLOGY vol. 2, no. 4, April 2003, pages 215 - 220, XP004810319

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).